Back to search
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Clinicaltrials.gov:
EU CTIS:
#2025-521976-80-00
Other:
#79635322MMY2001
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Multiple Myeloma
Trial type
Interventional
Trial phase
Phase 2
Investigational
product
product
JNJ-79635322
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
February 8, 2026
Trial end date
December 12, 2028
CT.gov ID
#NCT07266441
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Primary outcome measures
- Overall Response Rate (ORR)
Secondary outcome measures
- Very Good Partial Response (VGPR) or Better Rate
- Complete Response (CR) or Better Rate
- Duration of Response (DoR)
- Progression-Free Survival (PFS)
- Overall Survival (OS)
- Time To Next Line of Therapy (TTNT)
- Number of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
- Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score
- Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score
- Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by European Quality of Life 5-Dimensions 5-Level Version (EQ-5D-5L) Scale Score
- Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by MySIm-Q
- Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
- Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EQ-5D-5L
- Percentage of Participants With Meaningful Improvement in Symptoms, Functioning, and HRQoL as Assessed by MySIm-Q
- Percentage of Participants With Meaningful Improvement in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
- Percentage of Participants With Meaningful Improvement in Symptoms, Functioning, and HRQoL as Assessed by EQ-5D-5L
- Serum Concentrations for JNJ-79635322
- Number of Participants With Anti JNJ-79635322 Antibodies
- Number of Participants With JNJ-79635322 Neutralizing Antibodies (NAb)
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
